Search research articles
Contact Us
Filters
Showing results (61-70 of 74) with videos related to
Page
of 8
Sort By:
European Urology Open Science
|
April 13, 2026
Role of Local Treatment to the Prostate in Patients With de Novo Low-volume Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Receptor Pathway Inhibitors
Philipp Mandel, Mike Wenzel, Felix Chun, et al.
Cancer Immunology, Immunotherapy : CII
|
May 27, 2025
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)
Matteo Santoni, Giandomenico Roviello, Enrique Grande, et al.
European Urology Focus
|
July 30, 2025
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study
Francesco Massari, Veronica Mollica, Ray Manneh Kopp, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 23, 2025
<sup>177</sup>Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 study
Philipp Mandel, Daniel Groener, Giulia Follacchio, et al.
Minerva Urology and Nephrology
|
June 23, 2026
Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study
Pasquale Rescigno, Tarek Taha, Maria J Fita, et al.
Targeted Oncology
|
October 1, 2024
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2<sup>EV</sup> Study
Ondřej Fiala, Francesco Massari, Umberto Basso, et al.
Clinical Genitourinary Cancer
|
April 16, 2023
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)
Matteo Santoni, Francesco Massari, Zin W Myint, et al.
Targeted Oncology
|
June 27, 2023
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study
Matteo Santoni, Francesco Massari, Zin W Myint, et al.
Minerva Urology and Nephrology
|
August 2, 2023
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
Camillo Porta, Aristotelis Bamias, Roubini Zakopoulou, et al.
European Urology Oncology
|
July 22, 2023
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Matteo Santoni, Sebastiano Buti, Zin W Myint, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 74) with videos related to
Sort By:
Page
of 8
European Urology Open Science
|
April 13, 2026
Role of Local Treatment to the Prostate in Patients With de Novo Low-volume Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Receptor Pathway Inhibitors
Philipp Mandel, Mike Wenzel, Felix Chun, et al.
Cancer Immunology, Immunotherapy : CII
|
May 27, 2025
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)
Matteo Santoni, Giandomenico Roviello, Enrique Grande, et al.
European Urology Focus
|
July 30, 2025
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study
Francesco Massari, Veronica Mollica, Ray Manneh Kopp, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 23, 2025
<sup>177</sup>Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 study
Philipp Mandel, Daniel Groener, Giulia Follacchio, et al.
Minerva Urology and Nephrology
|
June 23, 2026
Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study
Pasquale Rescigno, Tarek Taha, Maria J Fita, et al.
Targeted Oncology
|
October 1, 2024
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2<sup>EV</sup> Study
Ondřej Fiala, Francesco Massari, Umberto Basso, et al.
Clinical Genitourinary Cancer
|
April 16, 2023
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)
Matteo Santoni, Francesco Massari, Zin W Myint, et al.
Targeted Oncology
|
June 27, 2023
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study
Matteo Santoni, Francesco Massari, Zin W Myint, et al.
Minerva Urology and Nephrology
|
August 2, 2023
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
Camillo Porta, Aristotelis Bamias, Roubini Zakopoulou, et al.
European Urology Oncology
|
July 22, 2023
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Matteo Santoni, Sebastiano Buti, Zin W Myint, et al.
Page
of 8